Opinion
Video
Author(s):
Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering patient-specific factors.
Clinical Brief: Biomarker Testing Strategy in Second-Line Therapy
Main Discussion Topics:
Key Points for Physicians:
The discussion emphasized that endocrine resistance is a complex phenomenon involving multiple pathways, not just ESR1 mutations, requiring comprehensive biomarker assessment for optimal treatment selection.
2 Commerce Drive
Cranbury, NJ 08512